EKSO - Ekso Bionics Holdings, Inc.
| Previous Close | 0.5151 |
| Open | 0.5400 |
| Bid | 0.5200 x 800 |
| Ask | 0.5399 x 1000 |
| Day's Range | 0.5048 - 0.5333 |
| 52 Week Range | 0.4900 - 2.5500 |
| Volume | 362,276 |
| Avg. Volume | 473,528 |
| Market Cap | 40.284M |
| Beta (3Y Monthly) | 2.53 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3190 |
| Earnings Date | May 10, 2018 - May 11, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 1.95 |
- Thomson Reuters StreetEvents
Edited Transcript of EKSO earnings conference call or presentation 1-Aug-19 8:30pm GMT
Q2 2019 Ekso Bionics Holdings Inc Earnings Call
- GlobeNewswire
Ekso Bionics® Unveils the Next Generation Exoskeleton for Neurorehabilitation
Ekso Bionics Holdings, Inc. (EKSO), a leading developer of exoskeletons for medical and industrial use, today unveiled EksoNR, the next generation EksoGT— the most clinically used robotic exoskeleton. Developed for neurorehabilitation, EksoNR is an intuitive exoskeleton device that empowers patients recovering from stroke or other conditions to learn to walk again with a more natural gait. The device now includes new features and software enhancements to help physical therapists and patients get even more out of each rehabilitation session.
- Simply Wall St.
Do Institutions Own Shares In Ekso Bionics Holdings, Inc. (NASDAQ:EKSO)?
If you want to know who really controls Ekso Bionics Holdings, Inc. (NASDAQ:EKSO), then you'll have to look at the...
- GlobeNewswire
Ekso Bionics Reports Second Quarter 2019 Results
RICHMOND, Calif., Aug. 01, 2019 -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use,.
- GlobeNewswire
Ekso Bionics® to Report Second Quarter 2019 Financial Results on August 1, 2019
Ekso Bionics Holdings, Inc. (EKSO), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the second quarter 2019 after the close of trading on Thursday, August 1, 2019. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to discuss the financial results and recent business developments. Investors interested in listening to the conference call may do so by dialing (877) 407-3036 for domestic callers or (201) 378-4919 for international callers.
- GlobeNewswire
Ekso Bionics® Expands Its Medical Portfolio with Upper Body Exoskeleton for Rehabilitation
Ekso Bionics Holdings, Inc. (EKSO), an industry leader in exoskeleton technology for medical and industrial use, today announced the expansion of its medical exoskeleton portfolio with an upper extremity rehabilitation device called EksoUE. The wearable upper body exoskeleton assists patients with a broad range of upper extremity impairment and aims to provide them with a wider range of motion and increased endurance for rehabilitation sessions of higher dose and intensity. Through a collaboration between Ekso Bionics and The Johns Hopkins University School of Medicine, the concept of EksoUE was beta-tested by the KATA Design Studio.
- Simply Wall St.
Introducing Ekso Bionics Holdings (NASDAQ:EKSO), The Stock That Tanked 88%
Long term investing is the way to go, but that doesn't mean you should hold every stock forever. We really hate to see...
- Simply Wall St.
Ekso Bionics Holdings, Inc. (NASDAQ:EKSO): Time For A Financial Health Check
While small-cap stocks, such as Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) with its market cap of US$97m, are popular...
- GlobeNewswire
Ekso Bionics Announces Closing of $10 Million Public Offering
Ekso Bionics Holdings, Inc. (EKSO) (the “Company,” “Ekso” or “Ekso Bionics”), an industry leader in exoskeleton technology for medical and industrial use, announced today the closing of its previously announced underwritten public offering of 6,666,667 shares of its common stock and accompanying warrants to purchase 6,666,667 shares of its common stock, at a price to the public of $1.50 per share and accompanying warrant to purchase one share of common stock, for gross proceeds of $10.0 million before deducting underwriters’ discounts, commissions and estimated offering expenses. The securities described above were offered by the Company pursuant to a “shelf” registration statement on Form S-3 (File No. 333-218517) relating to the public offering of such securities, which was filed with the U.S. Securities and Exchange Commission (the “SEC”) on June 6, 2017 and declared effective by the SEC on June 16, 2017.
- GlobeNewswire
Ekso Bionics Announces Pricing of $10 Million Public Offering
Ekso Bionics Holdings, Inc. (EKSO) (the “Company,” “Ekso” or “Ekso Bionics”), an industry leader in exoskeleton technology for medical and industrial use, announced today the pricing of its previously announced underwritten public offering of 6,666,667 shares of its common stock and accompanying warrants to purchase 6,666,667 shares of its common stock, at a price to the public of $1.50 per share and accompanying warrant to purchase one share of common stock, for expected gross proceeds of $10.0 million before deducting underwriters’ discounts, commissions and estimated offering expenses. Cantor Fitzgerald & Co. is acting as lead book-running manager and SunTrust Robinson Humphrey, Inc. is acting as joint book-running manager for the offering.
- GlobeNewswire
Ekso Bionics Announces Proposed Public Offering of Common Stock and Warrants
Ekso Bionics Holdings, Inc. (EKSO) (the “Company,” “Ekso” or “Ekso Bionics”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it is commencing an underwritten public offering of shares of its common stock and warrants to purchase shares of its common stock. All the shares and warrants to be sold in the offering will be offered by Ekso. The Company intends to use the net proceeds, if any, from the sale of the shares of common stock and warrants in the offering (and from the exercise, if any, of the warrants issued in the offering) for general corporate purposes, which may include acquisitions, research and development activities, capital expenditures, selling, general and administrative costs, facilities expansion, and to meet working capital needs.
- Thomson Reuters StreetEvents
Edited Transcript of EKSO earnings conference call or presentation 1-May-19 8:30pm GMT
Q1 2019 Ekso Bionics Holdings Inc Earnings Call
- GlobeNewswire
Ekso Bionics®’ EksoGT Exoskeleton Adopted in Singapore for Groundbreaking Clinical Study
Ekso Bionics Holdings, Inc. (EKSO), an industry leader in exoskeleton technology for medical and industrial use, today announced that the National University Health System (NUHS) in Singapore has adopted three EksoGT exoskeletons for a groundbreaking clinical study. NUHS is one of the first national health systems in Asia to study how advanced exoskeleton technology can improve mobility and rehabilitation outcomes, and the first to study it across the entire continuum of care. The Improving Mobility via Exoskeletons (iMOVE) program, supported by Temasek Foundation and Trailblazer Foundation Limited, will study patient outcomes and assess the viability and potential for scaling-up the use of robotic exoskeletons across the continuum of rehabilitation care from hospital to community. The study will focus on patients suffering from stroke and spinal cord injuries, especially for the elderly. The three EksoGT devices will be used at multiple NUHS partner sites including Alexandra Hospital, NTUC Health, St Luke’s Eldercare, St Luke’s Hospital, and Stroke Support Station.
- GlobeNewswire
Ekso Bionics Announces Appointment of Bill Shaw as Chief Commercial Officer
Ekso Bionics Holdings, Inc. (EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced the appointment of Bill Shaw as Chief Commercial Officer, with a start date of May 6, 2019. Mr. Shaw will be responsible for overseeing Ekso Bionics’ global commercialization strategy and will focus on accelerating adoption of the Company’s medical technologies. Mr. Shaw brings more than 15 years of medical device sales and leadership experience to Ekso Bionics. Most recently, Mr. Shaw served as Global Vice President of Robotic Surgery at Zimmer Biomet.
- GlobeNewswire
Kindred Hospital Rehabilitation Services Expands Pilot of Ekso Bionics®’ EksoGT Exoskeleton to Enhance Stroke Rehabilitation Offering
Ekso Bionics Holdings, Inc. (EKSO), an industry leader in exoskeleton technology for medical and industrial use, today announced that Kindred Hospital Rehabilitation Services ("Kindred"), a division of Kindred Healthcare, has expanded their pilot of the EksoGT exoskeleton to offer advanced stroke rehabilitation at the majority of their sites - over 20 freestanding inpatient Kindred rehabilitation hospitals in 13 states. The pilot began over a year ago and has since been expanded to the majority of their sites, making Kindred Ekso Bionics’ largest partner offering EksoGT at the most locations within a single network. “It is our mission to provide greater access to advanced rehabilitation, and we are excited to incorporate the EksoGT into our offering at most of our inpatient rehabilitation hospitals,” said Russ Bailey, COO/Senior Vice President of Operations at Kindred.
- Zacks
Ekso Bionics (EKSO) Reports Q1 Loss, Lags Revenue Estimates
Ekso Bionics (EKSO) delivered earnings and revenue surprises of -25.00% and -9.08%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press
Ekso Bionics: 1Q Earnings Snapshot
On a per-share basis, the Richmond, California-based company said it had a loss of 10 cents. The robotic exoskeleton company posted revenue of $3.6 million in the period. In the final minutes of trading ...
- GlobeNewswire
Ekso Bionics Reports First Quarter 2019 Results
RICHMOND, Calif., May 01, 2019 -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today.
- GlobeNewswire
Ekso Bionics® to Report First Quarter 2019 Financial Results on May 1, 2019
Ekso Bionics Holdings, Inc. (EKSO), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the first quarter 2019 after the close of trading on Wednesday, May 1, 2019. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to discuss the financial results and recent business developments. Investors interested in listening to the conference call may do so by dialing (877) 407-3036 for domestic callers or (201) 378-4919 for international callers.
- Simply Wall St.
What Do Analysts Think About Ekso Bionics Holdings, Inc.’s (NASDAQ:EKSO) Earnings Outlook?
The latest earnings announcement Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) released in December 2018 signalled company earnings became less negative compared to the previous year's level - great news for investorsRead More...
- Thomson Reuters StreetEvents
Edited Transcript of EKSO earnings conference call or presentation 28-Feb-19 9:30pm GMT
Q4 2018 Ekso Bionics Holdings Inc Earnings Call
- GlobeNewswire
Ekso Bionics Reports Fourth Quarter and Year End 2018 Results
RICHMOND, Calif., Feb. 28, 2019 -- Ekso Bionics Holdings, Inc. (NASDAQ: EKSO), an industry leader in exoskeleton technology for medical and industrial use, today reported.
- GlobeNewswire
Ekso Bionics® to Report Fourth Quarter and Full Year 2018 Financial Results on February 28, 2019
Ekso Bionics Holdings, Inc. (EKSO), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the fourth quarter and full year 2018 after the close of trading on Thursday, February 28, 2019. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to discuss the financial results and recent business developments. Investors interested in listening to the conference call may do so by dialing (877) 407-3036 for domestic callers or (201) 378-4919 for international callers.
- ACCESSWIRE
4 Healthcare Stocks Looking To Finish Strong On Wednesday (1/30/19)
Premier Health Group (PHGRF) (PHGI), China SXT Pharmaceuticals Inc (SXTC), eHealth Inc (EHTH), and Ekso Bionics Holdings Inc (EKSO) represent four healthcare companies determined to provide the best quality of care for consumers in need. The Company has seen impressive gains over the last few months as a result of momentum gained from several key strategic investments meant to demonstrate to both investors and consumers that the Company is determined to invest in the future of its customers. Premier Health Group (PHGRF) (PHGI) announced earlier this week that, further to its new release dated January 10, 2019, the Company has acquired all outstanding securities of Cloud Practice Inc. As a result of the acquisition, Cloud Practice's Founders, including CEO Jordan Visco, and entire support team, consisting of several software developers and sales staff, will join and work alongside the Premier Health team to offer tools and resources providing for better efficiency on a day-to-day basis for both physicians and customers.
